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Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus
disease 2019 (COVID-19) pandemic. As patients recover from COVID-19, some continue to report persisting
symptoms weeks to months after acute infection. These effects have been referred to as post-acute sequelae
of SARS-CoV-2 infection (PASC). We report the case of a 38-year-old woman suffering from PASC symptoms
following acute COVID-19 in October 2020. During her acute infection phase, she had a home recovery and
reported her predominant symptoms as fatigue, headaches, body pain, and shortness of breath. After most
of her symptoms were resolved, she continued to have periodic episodes of fatigue and headaches, along
with random shortness of breath while at rest and during activities for months beyond the acute phase of the
illness. She also noted the presence of “brain fog,” as if lacking the same clarity that she had prior to her
illness. These symptoms persisted for three months before the patient underwent enhanced external
counterpulsation (EECP) therapy in one-hour sessions, three times per week. This therapy was chosen based
on the mechanism of action of EECP benefiting patients with ischemic cardiovascular diseases. After one
week, her “brain fog” had improved, with shortness of breath improving after 1.5 weeks. The patient
reported returning to pre-COVID health and fitness after approximately five weeks of EECP treatment. To
our knowledge, this is the first case of using EECP for post-COVID shortness of breath, fatigue, and “brain
fog.”
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Introduction
In the unprecedented times of the coronavirus disease 2019 (COVID-19) pandemic, there are increasing
reports of persistent symptoms weeks to months after recovery from acute COVID-19 [1]. This is a case of
long-term effects following acute COVID-19, characterized by fatigue, dyspnea, and “brain fog” (an inability
or difficulty in concentrating or focusing). Many people in this population have considered themselves as
“COVID-19 long haulers” or suffer from “long COVID.” Recently, the National Institutes of Health have
named the condition as post-acute sequelae of SARS-CoV-2 infection (PASC). Here, we present a case of
PASC that was treated with enhanced external counterpulsation (EECP).
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Case Presentation
In October 2020, a 38-year-old Hispanic woman with no preexisting health conditions noted the onset of
what she was certain to be her usual allergy symptoms, including itchy eyes, sneezing, sinus drainage, and
headache. She was generally healthy and was aware of standard COVID19 precautions being a working
healthcare professional. As a precautionary measure she took an additional temperature measurement,
which came to be normal. Overnight, she noticed a new onset of fever, severe body aches, and pronounced
fatigue. The next day she was tested for both influenza A/B and COVID-19 via antigen test, with a negative
flu result but a positive COVID-19 result. For verification, she also took a COVID-19 polymerase chain
reaction test that also resulted in a positive for infection. She was prescribed conventional therapy at the
time, including a cocktail of three vitamins (vitamin D-3 2,000 IU daily, zinc 50 mg daily, and vitamin C 500
mg daily), hydroxychloroquine 200 mg twice daily for six days, and Tylenol 500 mg two tablets every four to
six hours as needed. She had an at-home recovery and reported her predominant symptoms during the acute
phase as fatigue, headaches, body pain, and shortness of breath.
After most of her symptoms were resolved, she continued to have periodic episodes of fatigue and
headaches, along with random shortness of breath while at rest and during activities for months beyond the
acute phase of the illness. She also noted the presence of “brain fog,” as if lacking the same clarity that she
had prior to her illness. These symptoms persisted for three months before the patient underwent EECP for
one-hour sessions, three times per week. The patient underwent a non-standard EECP regimen of three days
per week for five weeks due to convenience. This therapy was chosen based on EECP’s unique mechanism of
action and the known cardiac and extra-cardiac effects. After one week, her “brain fog” had improved, with
shortness of breath improving after 1.5 weeks. The patient reported returning to pre-COVID-19 health and

How to cite this article
Dayrit J, Verduzco-Gutierrez M, Teal A, et al. (April 07, 2021) Enhanced External Counterpulsation as a Novel Treatment for Post-acute COVID-19
Sequelae. Cureus 13(4): e14358. DOI 10.7759/cureus.14358

fitness after approximately five weeks of EECP treatment.

Discussion
Several population studies in post-COVID-19 patients have emerged around the world, ranging in follow-up
time from a few weeks to several months. An early study conducted during March-June 2020 by the United
States Centers for Disease Control and Prevention followed 274 patients at two to three weeks after initial
positive COVID-19 test. They found that 34% of the patients reported at least one symptom, the most
common symptoms included: cough (43%), fatigue (35%) congestion (30%), dyspnea (29%), confusion (20%)
and chest pain (20%) [1]. A prospective cohort study of 1,733 patients in Wuhan, China evaluated patients at
six months from symptom onset. The study found that 76% of the patients reported at least one symptom at
follow-up, most commonly: fatigue/muscular weakness (76%), dyspnea (26%), sleep difficulties (26%), and
anxiety/depression (23%) [2].
The underlying pathophysiology of PASC is still being understood. A leading hypothesis is that SARS-CoV-2
causes endothelial dysfunction by infecting endothelial cells around the body via the angiotensin converting
enzyme-2 receptor, prompting release of inflammatory cytokines and compromising the epithelialendothelial barrier at late stages of infection. Several studies assessing post-acute sequelae have found
changes in cardiovascular, pulmonary, and neuropsychiatric organ systems. Puntmann et al. performed
cardiac magnetic resonance imaging in 100 patients approximately 71 days after the initial COVID-19
diagnosis and found abnormal findings in 78% of the patients [3]. Huang et al. assessed pulmonary function
in 57 patients at one month after discharge, finding diffusing capacity for carbon monoxide (DLCO) below
80% of predicted in 53% of the patients, with higher incidences in patients with severe infection compared
to non-severe infection. Additionally, patients with severe COVID-19 had a mean 56 m shorter six-minute
walking distance compared to non-severe patients [4]. Zhou et al. assessed cognitive function and
inflammatory markers in 29 patients two to three weeks after infection, finding significant decreases in
cognitive function in the sustained attention domain along with significant elevations in c-reactive protein
[5]. Another study performed brain MRI in 51 COVID-19 patients three months after discharge, finding
decreases in cerebral blood flow and changes to white and gray matter in patients with severe infection [6].
These studies show the extent of severity we may see in PASC patients.
Based on the pathophysiological changes with PASC, EECP could be a suitable treatment method for such
patients. EECP is a Food and Drug Administration-approved, non-invasive outpatient therapy for patients
with chronic stable angina and/or heart failure of ischemic etiology. Standard therapy involves 35 one-hour
treatments over seven weeks. Patients lie on a treatment table where compressive cuffs (similar to large
blood pressure cuffs) are securely wrapped around their calves, thighs, and buttocks. These cuffs inflate in a
distal-to-proximal sequence during diastole and deflate simultaneously just prior to the onset of systole.
Inflation and deflation are specifically timed to the patient’s electrocardiogram to optimize therapeutic
benefit. This mechanical compression induces physiologic and biochemical changes in the vasculature,
leading to angiogenesis and increased coronary function. The compression produces pulsatile shear stress,
which has been associated with improvements in systemic endothelial function via modulation of
vasodilating (e.g., nitric oxide) and pro-inflammatory agents (e.g., tumor necrosis factor alpha) [7].
In patients with underlying cardiovascular disease, EECP has been shown to significantly improve Canadian
Cardiovascular Society angina class, Duke Activity Score Index, Seattle Angina Questionnaire, and sixminute walking distance, all of which are independent markers associated with mortality benefits. EECP has
also been shown to improve time to ST-segment depression, treadmill exercise duration, ejection fraction,
and cardiac output/efficiency [7].
The benefits of EECP are also evident in patients without underlying cardiovascular disease. A recently
published study showed improved exercise endurance in those with low-to-normal exercise endurance, as
well as in chronic obstructive pulmonary disease patients. Significant improvements in maximum oxygen
uptake (VO2-MaxKg) were seen after three weeks of EECP therapy [8]. Lastly, EECP has also been known to
enhance cerebral blood flow, collateralization in the ischemic regions of the brain, and cognitive function.
All these factors, in addition to improved endothelial function, contribute to the mechanisms by which
EECP may provide relief in patients with fatigue, dyspnea, chest pain, and “brain fog” symptoms.

Conclusions
To our knowledge, this is the first case of using EECP for post-COVID dyspnea, fatigue, and “brain fog.”
There are no current guidelines for the treatment of PASC, and management of the condition is largely based
on patient presentation and symptoms and requires the efforts of a multidisciplinary team. This initial case
report of a patient recovering from her post-acute COVID-19 symptoms suggests EECP may serve as a novel
treatment modality for the management of PASC. More data are needed to further validate these findings.
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